Uterine Sarcomas: Surgical Management, Adjuvant Therapy and Survival Outcome. Experience at Gujarat Cancer and Research Institute
Uterine Sarcomas: Surgical Management, Adjuvant Therapy and Survival Outcome. Experience at Gujarat Cancer and Research Institute
复制标题
子宫肉瘤：手术治疗、辅助治疗和生存结果。
DOI：
10.1007/s40944-018-0247-0
复制
发表时间：
2019
影响因子：
0.4
通讯作者：
Meeta Mankad
中科院分区：
文献类型：
--
作者：
Shilpa Patel;R. Tiwari;R. Arora;Pabashi Poddar;A. Desai;Meeta Mankad
背景：恶性肿瘤很少见，占所有子宫癌的7-8%，占所有女性生殖道癌的不到1%。手术是治疗的基础，根据疾病的分期，还可以进行放疗、化疗或激素治疗。由于其罕见性、异质性和侵袭性，关于最佳治疗方法没有共识，也缺乏证据。目的探讨子宫肉瘤的临床、病理特点、预后因素及转归分析。方法回顾性研究2001年1月至2013年12月在艾哈迈达巴德古吉拉特邦癌症研究所妇科肿瘤科发现的所有组织学证实的子宫肉瘤病例。回顾和记录患者的特点、肿瘤特征、各种治疗方式、手术细节、随访、复发和生存等资料。结果本组共纳入57例。平滑肌肉瘤是最常见的组织病理类型。1期24例，继续观察。在我们的研究中，近50%的患者在我们的研究期间复发。总体而言，64%的患者存活至3年，53%的患者存活至5年。26%的病例在治疗完成后的一年内死亡。结论子宫肉瘤发病率低，缺乏共识或指南，文献不足，治疗具有挑战性。辅助治疗应个体化。
BackgroundUterine sarcomas are rare, accounting for 7–8% of all uterine cancers and less than 1% of all female genital tract cancers. Surgery is a cornerstone in the treatment, and addition of radiotherapy, chemotherapy or hormonal therapy depends on the stage of the disease. Due to its rarity, heterogeneity and aggressiveness, there is no consensus and there is scarce evidence regarding the optimal therapeutic approaches.PurposeOur aim was to study the cases of uterine sarcoma in terms of clinical and histopathological characteristics, prognostic factors and outcome analysis.MethodsThis is a retrospective study of all cases of histological proven uterine sarcoma identified between January 2001 and December 2013 at the Department of Gynecologic Oncology, Gujarat Cancer and Research Institute, Ahmedabad. The data regarding the patients’ characteristics, tumor characteristics, various treatment modalities, operative details, follow-up, recurrence and survival were reviewed and recorded.ResultsTotal 57 were included in our study. Leiomyosarcoma was the most common histopathological type. Twenty-four cases were stage 1 and were kept on observation. Almost 50% of the patients in our study recurred during our study period. Overall 64% of the patients survived till 3 years and 53% till 5 years of follow-up. Twenty-six percent of the case died within first year of completion of treatment.ConclusionThe management of uterine sarcomas is challenging due to the rare occurrence, lack of consensus or guidelines and adequate literature. Adjuvant treatment should be individualized.